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Direct inspection of saphenous veins from patients
with venous dysfunction has shown that their valves
are fewer in number2-4 and that the existing valves
show evidence of damage.5 This damage is seen as
shortening, thickening, perforation, or splitting of the
leaflets.6,7 We have shown that, in saphenous veins
removed during surgical correction of venous insuffi-
ciency, monocytes are found on the endothelium and
in vein wall interstitium intimately associated with
interstitial macrophages and with intracellular adhe-
sion molecules (ICAM-1).8 This evidence suggests
that activated leukocytes may be related to valvular
damage and perhaps to weakness of the vein wall.
Because activated cells may release proteolytic
enzymes or reactive oxygen intermediates that cause
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Purpose: Cell activation may play an important role in the production of venous insuffi-
ciency, just as leukocytes participate in the cause of venous ulcer. If activated, monocytes
observed on venous endothelium can migrate into the venous wall and produce toxic
metabolites and free oxygen radicals that may participate in valve destruction and venous
wall weakening. At present, it remains uncertain to what degree leukocytes are actually
activated in patients. This study was designed to explore the level of activation and to
examine whether patient plasma contains an activator that leads to leukocyte activation
of unstimulated naive leukocytes from volunteers without venous insufficiency disease.
Methods: Twenty-one patients (4 men, 17 women), who ranged in age from 34 to 69 years
(mean age, 53.2 years), with chronic venous disease were compared with 16 healthy control
volunteers (4 men, 12 women), who ranged in age from 18 to 65 years (mean age, 48.4
years). All the patients underwent evaluation with Doppler ultrasound scanning and were
classified with the CEAP score.1 Nearly all the patients who smoked or were hypertensive
were excluded. The blood types (ABO and Rh) of the controls were matched to the study
group. Isolates of patient whole blood, plasma, or leukocytes were incubated with isolates of
control whole blood, plasma, or leukocytes to separate actual activation from spontaneously
observed activation. The granulocyte activation was measured with nitroblue tetrazolium
(NBT) reduction and quantitation of granulocyte pseudopod formation. Hydrogen perox-
ide production in patient plasma was measured with a recently developed electrode method. 
Results: Leukocytes from healthy blood and patient plasma had significantly higher
NBT-positive granulocyte counts than either patient blood, healthy blood, or patient
blood incubated in healthy plasma. In a comparison of patient groups across the CEAP
classes, the NBT-positive granulocyte counts were significantly greater in classes 4, 5,
and 6 than in classes 2 and 3 (P < .001). Pseudopod formation was significantly greater
in mixtures of granulocytes in healthy blood and patient plasma than in all other groups.
There was no difference in the level of pseudopod formation in control leukocytes incu-
bated with patient plasma in patients across the CEAP spectrum. The patient plasma
produced significantly higher hydrogen peroxide values than did the controls.
Conclusion: These results suggest that patient plasma may contain an activating factor for
granulocytes. The finding that activated neutrophils were fewer in number in patient
whole blood than in healthy blood incubated in patient plasma could suggest that acti-
vated neutrophils in patients with chronic venous insufficiency might be trapped in the
peripheral circulation. It is unknown what factors in the plasma might induce activation
of naive neutrophils, but such activators could possibly be important in the pathogenesis
of primary venous dysfunction and the development of chronic venous insufficiency. 
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such tissue damage, the hypothesis was proposed
that soluble markers of leukocyte adhesion and acti-
vation could be detected in the plasma of individu-
als with venous insufficiency. If such an activator
were present in the plasma of patients, a potential
driving mechanism for venous insufficiency might be
identified that could become a target for future
interventions. Therefore, this study was carried out
to obtain direct evidence for cell activation in venous
blood samples of patients with venous insufficiency. 
PATIENTS AND METHODS
All the procedures for this study were conducted
with approval of the Human Subjects Committee of
the University of California, San Diego, and the
Scripps Memorial Hospital, La Jolla. A total of 21
patients (4 men, 17 women), who ranged in age
from 34 to 69 years (mean age, 53.2 ± 9.8 years),
with chronic venous disease who underwent surgical
treatment were studied (Table I). All the patients
were classified with the CEAP classification, and all
underwent evaluation for reflux of the greater saphe-
nous vein and elsewhere with Doppler ultrasound
scanning (Table I). For the most part, the subjects
who smoked cigarettes or were hypertensive were
excluded because of their known nonspecific activa-
tion of leukocytes.9 The patients with known or sus-
pected inflammatory disorders also were excluded.
Sixteen healthy control volunteers (4 men, 12
women), who ranged in age from 18 to 65 years
(mean, 48.4 ± 14.2 years), donated blood for the
studies. The volunteers were interviewed to exclude
inflammatory disease and were screened for venous
disease. After informed consent was given and after
the subject was in the supine position for 20 minutes,
20 mL of blood was drawn into heparinized tubes
from the antecubital vein of the volunteers. This pre-
caution was taken to prevent the stimulating effects
of the standing position on leukocyte activation.10
Also, the patients for surgery had a 20-minute inter-
val of lying on the operating table before the blood
samples were drawn. ABO and Rh testing was per-
formed on all the samples so that ABO and Rh blood
type could be matched between patients and con-
trols. All the samples were stored on ice and handled
gently to minimize spontaneous activation in vitro.
Blood sample preparation
The healthy granulocytes in control whole blood
(NG) were tested. Likewise, the patient granulocytes
in whole blood were tested (PG). These cells were
tested directly without separation to assess the level of
activation in the circulation. The remaining blood
sample was centrifuged at 3000 rpm at 4°C for 30
minutes to prepare platelet-poor plasma, which then
was centrifuged again in the same fashion. The result-
ing control plasma (Cp) or patient plasma (Pp) was
mixed with control whole blood containing naive
granulocytes (NG) in a volume ratio of 4:1. The pur-
pose of this exchange of plasma was to expose naive
granulocytes (NG) from a volunteer without evidence
of venous disease or significant leukocyte activation to
the plasma of patients or the plasma of controls. From
this point, we will refer to these leukocytes as naive
leukocytes to emphasize that these cells were from
asymptomatic individuals. The volume ratio of 4:1
was selected to ensure that the naive leukocytes were
suspended in almost 90% patient plasma, assuming a
hematocrit of 40%. The mixture was incubated at
37°C for 15 minutes before measurement of neu-
trophil activation.
As a negative control, a healthy plasma sample
from an AB+ healthy control was mixed with plasma
from controls in the same volume ratio of 4:1.
Control plasma prepared for comparison with patient
plasma was immediately frozen in liquid nitrogen,
stored at –70°C, and tested as described previously.
The mixtures of negative control and positive test
mixtures were incubated and studied in parallel.
Finally, we examined nitroblue tetrazolium (NBT)
reduction and pseudopod formation in four different
groups: (1) control whole blood with healthy granu-
locytes (NG) alone, (2) naive granulocytes mixed with
control plasma (NG + Cp), (3) patient whole blood
with patient granulocytes (PG) alone, and (4) naive
granulocytes mixed with patient plasma (NG + Pp).
Experimental procedure
NBT reduction. NBT solution (0.1 mL; l mg
NBT in 1 mL distilled water; Sigma, St Louis, Mo)
was incubated with 0.1 mL of fresh sample at 37°C for
10 minutes and then stored for 10 minutes at room
Table I. Demographic data of study patients
No. of individuals 21
Men:women 4:17
Mean age (years) 53.2 (range, 34 to 69)
CEAP class 3 14
CEAP class 4 6
CEAP class 5 1
Current smoker 3
Obesity 1
Hypertension 0
Birth control pill 2
Premarin 5
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temperature (23°C to 24°C). A blood smear was pre-
pared and dried. The slides were treated with 1 mL of
Wright’s stain (0.3 w/v buffered at pH 6.9 in
methanol; Sigma) for 15 seconds and 1 mL of distilled
water for 30 seconds at room temperature, rinsed with
distilled water, and then dried. Granulocytes that con-
tained the characteristic black crystals of formazan
from which NBT was reduced by superoxide genera-
tion in their cytoplasm were considered NBT positive.
However, granulocytes that contained platelets and
Fig 1. Micrographs of polymorphonuclear granulocytes showing tetrazolium crystal formation
after nitroblue tetrazolium reduction (A,B,C) and projection of pseudopods (D,E,F). Control
blood of individuals without symptoms (A,D), patient whole blood (B, E), and naive granulocytes
incubated in patient plasma (C, F). Bar represents 10 m m. Magnification is same for all panels.
quantities of hydrogen peroxide to buffer or human
plasma with sodium azide.12
Statistics. All the measurements are presented as
mean ± standard deviation. Mann-Whitney test was
performed for comparisons between control blood
and patient blood or mixtures of naive granulocytes
with control or patient plasma. Wilcoxon paired
signed rank test was performed for comparisons
between naive leukocytes after incubation in patient
and control plasma and for pair comparisons of
patient (or control) whole blood with naive leuko-
cytes incubated in patient (or control) plasma.
Pearson product moment correlations were used to
test relationships between NBT-positive values and
pseudopod formation values. In addition, simple
regression was performed to evaluate between NBT
reduction and pseudopod formation values.
Statistically significant differences were determined at
the P level of .05. All analyses were performed with
commercial software (StatView Version 4.5 for
MacIntosh, Abacus Concepts Inc, Berkeley, Calif).
RESULTS
NBT reduction. The NBT-positive cells were
counted in each sample. There was no difference in
NBT reduction between the control whole blood or
the naive granulocytes mixed with control plasma
(5.40 ± 1.91 vs 8.69 ± 2.84). This provided a nega-
tive control. Also, patient whole blood alone (7.86
± 6.90) compared with control whole blood or naive
cells mixed with control plasma exhibited no differ-
ences in NBT reduction. This provided negative
controls related to the manipulation of the samples.
Increased NBT reduction as a result of superox-
ide production was detectable when patient plasma
was applied to naive granulocytes (Fig 2). Control
blood cells containing naive leukocytes mixed with
patient plasma (14.3 ± 6.29) showed a significantly
greater level of NBT reduction than all of the other
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had formazan were not counted as positive (Fig 1A to
C). A total of 100 neutrophils per sample were count-
ed three times. The count is reproducible on average
within 1% if repeated by the same investigator. NBT
reduction can be blocked with superoxide dismu-
tase.11
Pseudopod formation. After the removal of an
aliquot of blood for the NBT test, the samples were
incubated for another 15 minutes at 37°C and sepa-
rated into plasma and cells with sedimentation at 1
g. Then, 0.1 mL of the supernatant layer containing
plasma, leukocytes, platelets, and sporadic erythro-
cytes was removed and added to 0.1 mL of 1% glu-
taraldehyde (Fisher Scientific, Fair Lawn, NJ) in 0.1
mol/L cacodylate buffer (Na[CH3]2AsO2/3H2O
in distilled water; Ted Pella Inc, Redding, Calif).
The cells were fixed for 30 minutes, and then crystal
violet in 70 mmol/L phosphate buffer was added to
stain the leukocyte nuclei in wet mount prepara-
tions. Freely suspended leukocytes with pseudopo-
dia (Fig 1D to F) were identified with their seg-
mented nuclei and presence of cytoplasmic granules.
A total of 100 cells were counted three times repeat-
edly. Cells with pseudopod projection greater than 1
m m were considered positive. The count is repro-
ducible on average within 2% if repeated by the same
investigator.
Hydrogen peroxide production in plasma.
Levels of hydrogen peroxide production in plasma
were measured with an electrode as described previ-
ously.12 Of the 21 patients in the study, five donated
blood for the H2O2 examination. Eleven other
patients also donated blood samples. Three men and
13 women (mean age, 46 ± 9 years) and 14 controls
(10 men, 4 women; mean age, 45 ± 4 years) without
evidence of venous disorders or hypertension were
enrolled (Table II). Briefly, fresh samples were pre-
pared for measurement with the placement of 1.5 mL
of blood in a 2-mL centrifuge tube followed by incu-
bation at 37°C for 10 minutes and centrifugation at
500 g for 10 minutes. After the sample preparation,
either sodium azide (20 m L of a 2 mol/L) or catalase
(20 m L containing 0.25 mg of the enzyme) was added
to approximately 0.75 mL of the plasma layer. The
plasma then was swiftly stirred without mixing the
buffy coat and red blood cell layer with the plasma.
The electrode was placed in the plasma, and its out-
put was recorded for 10 minutes. Measurements after
the addition of sodium azide and catalase were each
carried out in duplicate. The current obtained from
the plasma sample with catalase was subtracted from
the current with sodium azide. The difference
between these currents was ascribed to hydrogen per-
oxide and directly calibrated with additions of known
Table II. Demographic data of H2O2 study patients
No. of individuals 16
Men:Women 3:13
Mean age (years) 45 (range, 31 to 59)
CEAP class 3 14
CEAP class 4 1
CEAP class 5 0
CEAP class 6 1
Current smoker 1
Diabetes 0
Obesity 4
Hypertension 0
Birth control pill 2
Premarin 3
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combinations. The plasma from patients with chron-
ic venous insufficiency, CEAP classes 4 to 6, stimu-
lated about 2.7 times greater NBT-positive granulo-
cyte counts than did control plasma.
By means of microscopy, formazan crystals in
leukocytes were seen to be spotty and scattered in all
groups when leukocytes were activated. In contrast,
when naive cells were mixed with patient plasma, the
crystals were frequently clustered in larger aggre-
gates (Fig 1C).
Pseudopod formation. There was no statistical-
ly significant difference in frequency of granulocytes
with pseudopod formation in control whole blood as
compared with naive blood cells mixed with control
plasma (8.1 ± 3.4 vs 12.6 ± 5.5; P > .05). Also, patient
whole blood compared with control whole blood was
not statistically different (13.0 ± 9.45; P > .05).
In contrast, a significant increase in pseudopod
formation in the naive granulocytes was observed
after incubation with patient plasma (P < .001).
Control blood cells mixed with patient plasma
showed an average of 25.0 ± 14.7 leukocytes, with
pseudopod formation per 100 cells. This mixture also
had a significantly higher level of pseudopod forma-
tion than did the mixture of naive cells and control
plasma (Fig 3). The plasma from patients caused
about two times greater levels of pseudopod forma-
tion in naive granulocytes than were observed in
granulocytes of control blood without stimulation.
When examined with photomicrographs, pseudo-
pod projections in leukocytes from control whole
blood, naive cells mixed with control plasma, and
patient whole blood were small and narrow. In con-
trast, the pseudopod projections in naive cells mixed
with patient plasma were comparatively large and
wide and pointed in multiple directions (Fig 1F).
Level of activation in CEAP clinical classes.
There were no differences in NBT reduction and
pseudopod formation in untreated blood from
patients in class 2 as compared with class 3 or among
classes 4, 5, and 6. In contrast, there were significant
differences in NBT reduction and pseudopod for-
mation between granulocytes from patient whole
blood and naive granulocytes mixed with patient
plasma among classes 2 and 3 and classes 4, 5, and 6
(Figs 4, 5). Patient plasma from classes 4, 5, and 6
caused comparatively greater granulocyte activation
in terms of superoxide production and actin poly-
merization than did patient plasma from classes 2
and 3. However, the granulocytes in patient whole
Fig 2. Levels of nitroblue tetrazolium (NBT) reduction.
NG, Naive granulocytes; Cp, control plasma; PG, patient
granulocytes; Pp, patient plasma.
**P < .001 and †P < .0001, compared with naive granu-
locytes in patient plasma.
Fig 3. Levels of granulocyte pseudopod formation.
NG, Naive granulocytes; Cp, control plasma; PG, patient
granulocytes; Pp, patient plasma.
*P < .05 and †P < .0001, compared with naive granulo-
cytes in patient plasma.
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 1 Takase, Schmid-Schönbein, and Bergan 153
blood from the various clinical classes showed no
differences from one another with regard to NBT
reduction and pseudopod formation.
When naive neutrophils were mixed with plasma
from controls, the level of neutrophil activation
measured with NBT reduction and pseudopod for-
mation was significantly less than when the naive
neutrophils were mixed with patient plasma from
either classes 2 and 3 or classes 4, 5, and 6 (P < .05).
Correlation between NBT reduction and
pseudopod formation in chronic venous insuffi-
ciency. There was no correlation between NBT
reduction and pseudopod formation in untreated
control whole blood (r = 0.24, P = .93) or in con-
trol blood leukocytes mixed with control plasma (r =
0.28, P = .29). Nor was there any correlation
between NBT reduction and pseudopod formation
in patient whole blood from classes 4, 5, and 6 (r =
0.33, P = .50). There was no correlation between
the mixture of control blood cells and patient plas-
ma from classes 2 and 3 (r = 0.34, P = .24) and from
classes 4, 5, and 6 (r = 0.26, P = .59). There was a
weak correlation between the two forms of activa-
tion in whole blood from patients in classes 2 and 3
(r = 0.535, P = 0.47).
Plasma hydrogen peroxide production. The
average hydrogen peroxide production in the plasma
of patients was about 50% greater than in controls
(Fig 6). There was no significant correlation between
the number of NBT-positive neutrophils and the
hydrogen peroxide production in plasma.
DISCUSSION
The results of the current study suggest that
some aspects of leukocyte function are upregulated
in the circulation of patients with venous insufficien-
cy. The plasma exchange studies in which patient
plasma is applied to naive granulocytes derived from
individuals without any evidence of cardiovascular
dysfunction or venous disease suggest that the
patients carry a factor in the plasma that is related to
the upregulation. Granulocytes from patients exhib-
it reduced levels of activation after resuspension in
plasma from controls. The plasma of patients serves
as a source for free radical production.
We noted a lack of correlation between NBT
reduction and pseudopod formation. This was also
seen when CEAP classes 2 and 3 were compared with
CEAP classes 4, 5, and 6. This is in agreement with
similar observations made by us in studies with exper-
Fig 4. Comparison of nitroblue tetrazolium (NBT)
reduction. Patient samples were grouped into CEAP class-
es 2 and 3 and classes 4, 5, and 6.
NG, Naive granulocytes; Cp, control plasma; PG, patient
granulocytes; Pp, patient plasma.
*P < .05.
**P < .001.
Fig 5. Comparison of granulocyte pseudopod formation.
Patient samples were grouped into CEAP classes 2 and 3
and classes 4, 5, and 6.
NG, Naive granulocytes; Cp, control plasma; PG, patient
granulocytes; Pp, patient plasma.
*P < .05.
**P < .001.
imental animals in ischemic conditions. Unpublished
observations are in contrast to the strong correlation
between different forms of activation after stimulation
of leukocytes in vitro. After in vitro stimulation, dif-
ferent forms of activation follow a similar time course.
Direct observation of leukocytes in the microcircula-
tion suggests that cells are in different stages of activ-
ity in line with the lack of correlation in the present
study.
The activation of naive cells appears to induce
oxygen-free radical production as indicated by the
NBT reaction. Direct evidence of hydrogen ion pro-
duction obtained with the electrochemical hydrogen
peroxide measurements confirms this hypothesis.
Further evidence of activation of naive granulocytes
was provided with the observation of increased
pseudopod formation in these cells when they were
exposed to patient plasma. Although the former
reaction of hydrogen ion production parallels the
severity of venous disease, the latter reaction of
pseudopod formation does not.
The current selection of pseudopod formation
and NBT reduction as measures of cell activation is
motivated by two considerations. First, to detect the
levels of cell activation as they exist in vivo, in vitro
cell isolation techniques must be minimized. Also, it
is essential that fresh blood samples be tested. Both
the NBT reduction test and the rapid fixing of cells
for detection of spontaneous pseudopod formation
serve such a purpose. Second, both forms of activa-
tion, superoxide formation for NBT reduction and
actin polymerization during pseudopod projection,
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indicate important pathophysiologic processes in the
circulation. Cells that exhibit pseudopod formation
have a higher propensity to be trapped in the micro-
circulation,13-15 and superoxide formation consti-
tutes one of the first steps in the oxidative stress cas-
cade.16 As such, it is an important element in the
undesirable aspect of leukocyte activation, it is
encountered in a variety of ischemic diseases,17,18
and it may constitute a significant risk factor for the
development of venous valve damage and subse-
quent insufficiency. Direct evidence of superoxide
anion production obtained with the electrochemical
hydrogen peroxide measurements serves as addi-
tional support of this hypothesis.
Activated leukocytes may be more likely to adhere
to the endothelium in the pockets of venous valves and
may exhibit more enhanced levels of cytotoxity. This
hypothesis is in line with the increased infiltration of
leukocytes observed in the venous wall and valve leaflet
of patients with venous dysfunction.8 Also, this may be
associated with the enhanced expression of endothelial
adhesion molecules.19 Activation may be stimulated by
the production of specific humoral factors, such as
platelet-activating factor or complement frag-
ments,20,21 by depletion of endogenous deactivating
factors,17,22 or by a mere alteration in the fluid shear
stress. Shear changes are sufficient to affect gene
expression in endothelial cells or leukocytes.23
Leukocytes on the endothelium and in the venous wall
have been found to be more numerous on the proxi-
mal valve surface and adjacent wall where venous
hypertension is the greatest.
Examination of healthy veins and varicose veins
with light and transmission electron microscopy has
been reported by Obitsu et al.24 They concluded
that valve failure started with depression of the com-
missure of the valve with subsequent expansion of
the space between the valve cusps. In their study,
elongation of the cusps with bulbous thickening of
the free-edge cusp was noted and hyperplasia of the
collagen fibers in the valve cusp was detected. Our
own studies have shown a deterioration of collagen
in the valves and shortening of the valves, suggesting
valve damage.8
Coleridge Smith25 has presented a detailed
immunohistochemical study of eight varicose saphe-
nous vein samples and four healthy controls by
Wilkinson et al.26 Few infiltrating cells were found,
but those that were present were tissue macrophages
carrying the FCR1 receptor. Our own studies have
revealed a greater influx of cells, but they have been
monocytes that become macrophages after penetra-
tion of the endothelium.8
Fig 6. Hydrogen peroxide production levels in patients
with chronic venous insufficiency and in asymptomatic
controls.
Wilkinson et al26 apparently also found class II
major histocompatibility antigens on the endotheli-
um and did find macrophages in smooth muscle
cells in the thickened tunica media. They found
upregulation of HLA-D/DR in all three cell types,
but there was a preferential upregulation of HLA-
D/DQ in the smooth muscle cells. In general, the
function of the class II locus is to present processed
antigens to T-cells. The role of the D/DQ at this
site is uncertain and may be involved in the mainte-
nance of a chronic inflammatory process. The site of
D/DQ expression within the thickened media sug-
gests a possible active role within the development
of the venous insufficiency disorder.
Judging from the levels of activation alone, it may
be reasonable to combine limbs with CEAP classes 4,
5, and 6 as a single clinical entity because they all have
manifestations of inflammation and even infection.
Classes 4 and 5 exhibit inflammation, and class 6
implies infection as well. Classes 4, 5, and 6 represent
a group of individuals whose plasma, enhanced possi-
bly by the presence of inflammation, is capable of acti-
vating naive donor leukocytes. But even patient plas-
ma from more modest forms of venous insufficiency,
CEAP classes 2 and 3, show signs of cell activation.
This observation suggests that even in an earlier stage
of development of venous dysfunction, several mark-
ers for inflammation are present. A fundamental issue
in venous insufficiency is identification of the mecha-
nism for this early form of activation. The activation
process may constitute a potential new target for
pharmacologic or other intervention. A similar activa-
tion of circulating leukocytes has also been observed
in claudication.27
It is possible that, during the exposure of naive
granulocytes to patient plasma, a stabilizing effect or
an inhibitory factor on the cells is removed rather
than an activator added. With this hypothesis,
patient granulocytes do not respond because they
are unable to do so. Further, the cell activation in
this study might be related to venous insufficiency or
to subclinical inflammation alone or to a combina-
tion of both.
Clinically, leukocytes that project pseudopods
have a reduced probability of circulating systemical-
ly. This leads to a situation in which the full extent
of cell activation may not necessarily be identified
from tests performed on autologous systemic venous
blood samples. Our results indicating higher levels
of activation after incubation of naive granulocytes
with patient plasma than detected in autologous
blood are in line with the hypothesis that the fully
activated cells do not circulate and are trapped in the
peripheral circulation. If fully activated cells are
trapped, one cannot assume that the pool of circu-
lating leukocytes is a well-mixed pool and exhibits a
uniform degree of activation.
It should be noted that in the analysis of results,
some of the observed values are small and the standard
deviations are large. This may be a result of the small
number of observations made on biologically diverse
individuals. Also, it could be hypothesized that venous
hypertension is associated with the phenomenon of
leukocyte trapping. This would explain the absence of
such trapping in the upper extremities and portal sys-
tem in patients with severe venous insufficiency. In
addition, this may explain the findings of severe chron-
ic venous insufficiency in the upper extremities that
contain a functioning arteriovenous fistula and proxi-
mal subclavian venous obstruction.28,29
We expected that the level of activation produced
by patient plasma on naive leukocytes would corre-
late with the severity of venous insufficiency. The
CEAP classification stratifies limbs according to the
severity of their clinical findings, but patient plasma
samples from those individuals with the most florid
three classes of venous insufficiency were indistin-
guishable from one another. This may be a sign that
chronic upregulation may serve as a cell injury
mechanism. Restructuring of venous vessels may
depend on the duration of an upregulated state
rather than only the severity of the upregulation in
the venous blood. This is suggested by the fact that
clinical manifestations of venous insufficiency do
progress with time (eg, varicose veins and telangiec-
tasias enlarge). A shift from one CEAP class to the
next does not necessarily necessitate higher levels of
activation but only a longer duration of action.
Patient plasma, even in the lower CEAP classifica-
tion with uncomplicated varicose veins, did differ
from that of healthy individuals.
The evidence that the plasma of patients contains
an activator for granulocytes constitutes a particular
challenge. Although the specific biochemical identity
of this factor is unknown, it is possible that this factor
may not serve to upregulate only granulocytes but also
other circulating cells and endothelial cells and possi-
bly even interstitial cells. The factor may be important
in the pathogenesis of primary venous dysfunction and
the cause of chronic venous insufficiency.
CONCLUSIONS
These results suggest that patient plasma may
contain an activating factor for granulocytes. The
finding that activated neutrophils were fewer in
number in patient whole blood than in healthy
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blood incubated in patient plasma could suggest that
activated neutrophils in patients with chronic venous
insufficiency might be trapped in the peripheral cir-
culation. It is unknown what factors in the plasma
might induce activation of naive neutrophils, but
such activators could possibly be important in the
pathogenesis of primary venous dysfunction and the
development of chronic venous insufficiency.
We thank Mrs Rebecca Fung and Mr Fleming Chu for
their excellent assistance with the execution of the mea-
surements.
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